Monday, October 3, 2022


Biotechnology News Magazine

Jackson ImmunoResearch Announces New Range of Detection Reagents for R&D & Diagnostic Markets

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Jackson ImmunoResearch, manufacturer of secondary antibodies and immunoreagents for the life science market, announces a new range of detection reagents that offer superior imaging quality.

Jackson ImmunoResearch Nano Secondaries are polyclonal VHH Fragment antibodies (Nanobodies*) produced in Alpacas. They are available with specificity to Human, Rabbit, or Mouse. 10x smaller than conventional whole IgG antibodies, the <15KDa VHH Fragment antibodies are perfect for imaging experiments where good penetration is necessary. Nano Secondary antibodies are cross-adsorbed for exquisite specificity against target species with minimal cross-reactivity to other commonly used species, making them suitable for application in multiple labeling experiments.

Polyclonal detection reagents continue to offer the best signal strength by amplifying signal, even from poorly expressing targets. Offering a heterogeneous population of antibodies, each detecting a different portion of the primary antibody, the polyclonal Nano Secondary can increase labeling efficiency, resulting in brighter signal. They are available conjugated to reporter enzymes and a range of fluorescent dyes, including Alexa Fluor®, providing scope for high-resolution Immunohistochemistry and Immunofluorescence, making them an indispensable tool in both research and diagnostics imaging.

David A. Fancy, Ph.D., COO, commented, “We are really excited to launch Jackson ImmunoResearch Nano Secondaries to the marketplace. The single-domain antibody market is exploding; these antibodies are 1/10th the size of canonical immunoglobulins, making them ideal for drug delivery and super-resolution imaging, among many other potential uses.”

Nano Secondaries are now available for purchase directly from Jackson ImmunoResearch or through official distribution partners worldwide.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine